eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

摘要

Background & AimsRenal toxicity of first generation protease inhibitors (PIs) was not a safety signal in phase III clinical trials, but was recently reported in recent studies. It appeared important to determine the clinical significance of these findings.